SEOM clinical guidelines for the management of germ cell testicular cancer (2016).

Autor: Aparicio J; Servicio de Oncología Médica, Hospital Universitario y Politécnico La Fe, Av. Abril Martorell 106, 46026, Valencia, Spain. japariciou@seom.org., Terrasa J; Hospital Universitario Son Espases, Palma de Mallorca, Spain., Durán I; Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Sevilla, Spain., Germà-Lluch JR; Institut Català d'Oncologia, ICO-IDIBELL L'Hospitalet, Barcelona, Spain., Gironés R; Hospital Lluis Alcanyis, Xátiva, Spain., González-Billalabeitia E; Hospital Universitario Morales Meseguer-IMIB, Universidad Católica de Murcia-UCAM, Murcia, Spain., Gumà J; Hospital Universitario Sant Joan de Reus, URV, IISPV, Reus, Spain., Maroto P; Hospital de Sant Pau, Barcelona, Spain., Pinto A; Hospital Universitario La Paz, Madrid, Spain., García-Del-Muro X; Institut Català d'Oncologia, ICO-IDIBELL L'Hospitalet, Barcelona, Spain.
Jazyk: angličtina
Zdroj: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2016 Dec; Vol. 18 (12), pp. 1187-1196. Date of Electronic Publication: 2016 Nov 04.
DOI: 10.1007/s12094-016-1566-1
Abstrakt: Testicular cancer represents the most common malignancy in males aged 15-34 years and is considered a model of curable neoplasm. Maintaining success, reducing treatment burden, and focusing on survivorship are then key objectives. Inguinal orchiectomy is the first recommended maneuver that has both diagnostic and therapeutic aims. Most patients are diagnosed with stage I disease (confined to the testicle). Close surveillance and selective, short-course adjuvant chemotherapy are accepted alternatives for these cases. In patients with more advanced disease (stages II and III), 3-4 courses of cisplatin-based chemotherapy (according to IGCCCG risk classification) followed by the judicious surgical removal of residual masses represent the cornerstone of therapy. Poor-risk patients and those failing a first-line therapy should be referred to specialized tertiary centers. Paclitaxel-based conventional chemotherapy and high-dose chemotherapy plus autologous hematopoietic support can cure a proportion of patients with relapsing or refractory disease.
Competing Interests: The authors have declared that they have no potential conflicts of interest related to the publication of this manuscript.
Databáze: MEDLINE
Externí odkaz: